Diagnosis of ZD1839 resistant tumors

• US 20050059012A1
• Filed: 07/31/2003
• Published: 03/17/2005
• Est. Priority Date: 07/31/2002
• Status: Abandoned Application

• Current Assignee: Cedars-Sinai Medical Center (Cedars Sinai Health System)
• Original Assignee: Cedars-Sinai Medical Center (Cedars Sinai Health System)
• Inventors: Afar, Daniel, Mack, David H., Agus, David
• Application Number:
  US10/633,486
• Publication Number:
  US 20050059012A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07H 21/04 with deoxyribosyl as saccharide radical
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds

Abstract

Described herein are genes whose expression are regulated in specific cancers. Related methods and compositions that can be used for diagnosis of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.

Claims

1. A method of detecting a cancer-associated transcript in a cell from a patient, comprising contacting a sample obtained from a patient with a polynucleotide that selectively hybridizes to a nucleic acid sequence as shown in Tables 1A-C.

2. The method of claim 1, wherein the patient is suspected of suffering from a cancer.

3. The method of claim 2, wherein the cancer is ZD 1839 resistant.

4. The method of claim 1, wherein the patient suffers symptoms of a neoplastic disease.

5. The method of claim 1, wherein the patient is undergoing a therapeutic regimen to treat a neoplastic cancer or condition.

6. The method of claim 1, wherein the sample comprises isolated nucleic acids.

7. The method of claim 6, wherein the isolated nucleic acids are mRNA.

8. The method of claim 6, further comprising the step of amplifying the isolated nucleic acids before the step of contacting the sample with the polynucleotide.

9. The method of claim 1, wherein the nucleic acid sequence is SEQ ID NO:

2.

10. The method of claim 1, wherein the polynucleotide is immobilized on a solid surface.

11. An expression vector comprising a nucleic acid sequence as shown in Tables 1A-C.

12. The expression vector of claim 11, wherein said nucleic acid sequence is SEQ ID NO:

2.

13. A host cell comprising the expression vector of claim 11.

14. An antibody that binds to a polypeptide having a nucleic acid sequence as shown in Tables 1A-C.

15. The antibody of claim 14, wherein said polypeptide is SEQ ID NO:

1.

16. The antibody of claim 14, further conjugated to an effector component.

17. The antibody of claim 16, wherein the effector component is a fluorescent label.

18. The antibody of claim 17, wherein the effector component is a radioisotope or a cytotoxic chemical.

19. An antibody fragment wherein said antibody fragment binds to the polypeptide of claim 14.

20. The antibody of claim 14, wherein said antibody is a humanized antibody.

21. A method of detecting a cancer cell in a sample from a patient, comprising contacting a sample from a patient with the antibody of claim 14.

22. The method of claim 21, wherein the antibody is further conjugated to an effector component.

23. The method of claim 22, wherein the effector component is a fluorescent label.

24. A method for identifying a compound that modulates a cancer-associated polypeptide comprising the steps of:

a) contacting a compound with a cancer-associated polypeptide, the polypeptide encoded by a polynucleotide sequence as shown in Tables 1A-C; and

b) determining the functional effect of the compound upon the polypeptide.

25. A drug screening assay comprising the steps of

a) administering a test compound to a mammal having a cancer, or a cell isolated therefrom;

b) comparing the level of gene expression of a polynucleotide that selectively hybridizes to a sequence as shown in Tables 1A-C in a treated cell or mammal with the level of gene expression of the polynucleotide in a control cell or mammal, wherein a test compound that modulates the level of expression of the polynucleotide is a candidate for the treatment of the cancer.